In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1

Antiviral Therapy

Volumn 10, Issue 2, 2005, Pages 343-348

  Margot, Nicolas A ^a   Miller, Michael D ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EMTRICITABINE; INOSINATE DEHYDROGENASE; LAMIVUDINE; NELFINAVIR; NUCLEOSIDE ANALOG; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SAFETY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SUPERINFECTION; CELL LINE; CYTOPATHOGENIC EFFECT; DOSE RESPONSE; DRUG EFFECT;

ADENINE; ANTIVIRAL AGENTS; CELL LINE; CYTOPATHOGENIC EFFECT, VIRAL; DIDANOSINE; DIDEOXYNUCLEOSIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HIV-1; HUMANS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; RIBAVIRIN;

EID: 22844439291     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Sherman KE, Rouster SD, Chung RT & Rajicic N. Hepatitis C virus prevelance among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clinical Infectious Diseases 2002; 34:831-837.
2. McHutchison JG & Patel K. Future therapy of hepatitis C. Hepatology 2002; 36:S245-S252.
3. Fleischer R, Boxwell D & Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clinical Infectious Diseases 2004; 38:E79-E80.
4. Moreno A, Quereda C, Moreno L, Perez-Elias MJ, Muriel A, Casado JL, Antela A, Dronda F, Navas E, Barcena R & Moreno S. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antiviral Therapy 2004; 9:133-138.
5. Kakuda TN & Brinkman K. Mitochondrial toxic effects and ribavirin. Lancet 2001; 357:1802-1803.
6. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silbermann B & Sogni P. Mitochondrial toxic effects and ribavirin. Lancet 2001; 357:1803-1804.
7. Balzarini J, Naesens L, Robins MJ & De Clercq E. Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2′,3′-dideoxyinosine and 2′,3′-dideoxy-2,6-diaminopurine riboside. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1990; 3:1140-1147.
8. Hartman NR, Ahluwalia GS, Cooney DA, Mitsuya H, Kageyama S, Fridland A, Broder S & Johns DG. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Molecular Pharmacology 1991; 40:118-124.
9. Balzarini J, Lee C-K, Herdewijn P & De Clercq E. Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′- dideoxyinosine against human immunodeficiency virus. Journal of Biological Chemistry 1991; 266:21509-21514.
10. Gu Z, Salomon H, Cherrington JM, Mulato AS, Chen MS, Yarchoan R, Foli A, Sogocio KM & Wainberg MA. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonyl- methoxyethyl)adenine. Antimicrobial Agents & Chemotherapy 1995; 39:1888-1891.
11. Weislow OS, Kiser R, Fine DL, Bader J, Shoemaker RH & Boyd MR. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. Journal of the National Cancer Institute 1989; 81:577-586.
12. Prichard MN, Aseltine KR & Shipman C Jr. MacSynergy™ II, Version 1.0. 1993. Ann Arbor, MI: University of Michigan.
13. Prichard MN & Shipman C Jr. A three-dimensional model to analyze drug-drug interactions. Antiviral Research 1990; 14:181-205.
14. Glue P, Schenker S, Gupta S, Clement RP, Zambas D & Salfi M. The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. British Journal of Clinical Pharmacology 2000; 49:417-421.
15. Baba M, Pauwels R, Balzarini J, Herdewijn P, De Clercq E & Desmyter J. Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′- dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides of replication of human immunodeficiency virus in vitro. Antimicrobial Agents & Chemotherapy 1987; 31:1613-1617.
16. Klein MB, Campeol N, Lalonde RG, Brenner B & Wainberg MA. Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. AIDS 2003; 17:1001-1008.
17. Vogt MW, Hartshorn KL, Furman PA, Chou TC, Fyfe JA, Coleman LA, Crumpacker C, Schooley RT & Hirsch MS. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987; 235:1376-1379.
18. Hoggard PG, Veal GJ, Wild MJ, Barry MG & Back DJ. Drug interactions with zidovudine phosphorylation in vitro. Antimicrobial Agents & Chemotherapy 1995; 39:1376-1378.
19. Hoggard PG, Kewn S, Barry MG, Khoo SH & Back DJ. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrobial Agents & Chemotherapy 1997; 41:1231-1236.
20. Morsica G, De Bona A, Foppa CU, Sitia G, Finazzi R & Lazzarin A. Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment. AIDS 2000; 14:1656-1658.
21. Landau A, Batisse D, Piketty C, Jian R & Kazatchkine MD. Lack of interference between ribavirin and nucleoside analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. AIDS 2000; 14:1857-1858.